FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018183727> ?p ?o ?g. }

• W2018183727 endingPage "1163" @default.
• W2018183727 startingPage "1156" @default.
• W2018183727 abstract "This manuscript reports the assessment of pharmacodynamic (PD) markers of anti-coagulation in the first-in-man study with the novel direct Factor Xa (FXa) inhibitor, otamixaban, with a brief description of safety and pharmacokinetic (PK) findings. The study comprised ten consecutive parallel groups of healthy male subjects (6 active, 2 placebo per group). Eight groups received escalating intravenous doses of otamixaban as 6-hour infusions (1.7 to 183 microg/kg/h) and two groups received a bolus dose (30 or 120 microg/kg) with a 6-hour infusion (60 or 140 microg/ kg/h, respectively). PD markers included anti-FXa activity and clotting time measurements, i.e. activated Thromboplastin Time (aPTT), Prothrombin Time (PT), Heptest Clotting Time (HCT), and Russell's Viper Venom-induced clotting Time (RVVT). In addition, Endogenous Thrombin Potential (ETP) was assessed in the bolus-plus-infusion dose groups. Otamixaban was well tolerated. Otamixaban plasma concentrations increased with escalating dose, were maximal at the end-of-infusion (C(eoi)), and decreased rapidly as the infusion was stopped. Anti-FXa activity coincided with otamixaban plasma concentrations and clotting time measurements followed the same pattern. Maximal changes from baseline at C(eoi) were 1.9 +/- 0.2 for aPTT, 2.0 +/- 0.2 for PT, 5.1 +/- 0.6 for HCT, and 4.5 +/- 1.2 for RVVT. Otamixaban inhibited thrombin generation (24% decrease in ETP) and a delay in thrombin generation was noticed in vitro at high concentrations." @default.
• W2018183727 created "2016-06-24" @default.
• W2018183727 creator A5003622982 @default.
• W2018183727 creator A5019359875 @default.
• W2018183727 creator A5024030529 @default.
• W2018183727 creator A5054348847 @default.
• W2018183727 creator A5068034717 @default.
• W2018183727 creator A5072568369 @default.
• W2018183727 creator A5082821590 @default.
• W2018183727 creator A5083871238 @default.
• W2018183727 date "2005-01-01" @default.
• W2018183727 modified "2023-10-18" @default.
• W2018183727 title "Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor" @default.
• W2018183727 cites W1546296190 @default.
• W2018183727 cites W164295419 @default.
• W2018183727 cites W1753709933 @default.
• W2018183727 cites W1827805086 @default.
• W2018183727 cites W1837090086 @default.
• W2018183727 cites W1980315530 @default.
• W2018183727 cites W2023320697 @default.
• W2018183727 cites W2025468677 @default.
• W2018183727 cites W2028374530 @default.
• W2018183727 cites W2042190470 @default.
• W2018183727 cites W2053420707 @default.
• W2018183727 cites W2053677326 @default.
• W2018183727 cites W2058310514 @default.
• W2018183727 cites W2081561904 @default.
• W2018183727 cites W2091027505 @default.
• W2018183727 cites W2096435224 @default.
• W2018183727 cites W2099094229 @default.
• W2018183727 cites W2107689457 @default.
• W2018183727 cites W2119768870 @default.
• W2018183727 cites W2120739142 @default.
• W2018183727 cites W2127489984 @default.
• W2018183727 cites W2146861255 @default.
• W2018183727 cites W2158336299 @default.
• W2018183727 cites W2748139581 @default.
• W2018183727 doi "https://doi.org/10.1160/th05-05-0347" @default.
• W2018183727 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16411387" @default.
• W2018183727 hasPublicationYear "2005" @default.
• W2018183727 type Work @default.
• W2018183727 sameAs 2018183727 @default.
• W2018183727 citedByCount "23" @default.
• W2018183727 countsByYear W20181837272012 @default.
• W2018183727 countsByYear W20181837272014 @default.
• W2018183727 countsByYear W20181837272021 @default.
• W2018183727 crossrefType "journal-article" @default.
• W2018183727 hasAuthorship W2018183727A5003622982 @default.
• W2018183727 hasAuthorship W2018183727A5019359875 @default.
• W2018183727 hasAuthorship W2018183727A5024030529 @default.
• W2018183727 hasAuthorship W2018183727A5054348847 @default.
• W2018183727 hasAuthorship W2018183727A5068034717 @default.
• W2018183727 hasAuthorship W2018183727A5072568369 @default.
• W2018183727 hasAuthorship W2018183727A5082821590 @default.
• W2018183727 hasAuthorship W2018183727A5083871238 @default.
• W2018183727 hasConcept C111113717 @default.
• W2018183727 hasConcept C112705442 @default.
• W2018183727 hasConcept C126322002 @default.
• W2018183727 hasConcept C144594695 @default.
• W2018183727 hasConcept C186738567 @default.
• W2018183727 hasConcept C2776301958 @default.
• W2018183727 hasConcept C2777091921 @default.
• W2018183727 hasConcept C2777292125 @default.
• W2018183727 hasConcept C2777987278 @default.
• W2018183727 hasConcept C2778205648 @default.
• W2018183727 hasConcept C2778261982 @default.
• W2018183727 hasConcept C2778382381 @default.
• W2018183727 hasConcept C2778589496 @default.
• W2018183727 hasConcept C2779161974 @default.
• W2018183727 hasConcept C2780077467 @default.
• W2018183727 hasConcept C2780434524 @default.
• W2018183727 hasConcept C2992139802 @default.
• W2018183727 hasConcept C42219234 @default.
• W2018183727 hasConcept C43376680 @default.
• W2018183727 hasConcept C71924100 @default.
• W2018183727 hasConcept C77171857 @default.
• W2018183727 hasConcept C89560881 @default.
• W2018183727 hasConcept C98274493 @default.
• W2018183727 hasConceptScore W2018183727C111113717 @default.
• W2018183727 hasConceptScore W2018183727C112705442 @default.
• W2018183727 hasConceptScore W2018183727C126322002 @default.
• W2018183727 hasConceptScore W2018183727C144594695 @default.
• W2018183727 hasConceptScore W2018183727C186738567 @default.
• W2018183727 hasConceptScore W2018183727C2776301958 @default.
• W2018183727 hasConceptScore W2018183727C2777091921 @default.
• W2018183727 hasConceptScore W2018183727C2777292125 @default.
• W2018183727 hasConceptScore W2018183727C2777987278 @default.
• W2018183727 hasConceptScore W2018183727C2778205648 @default.
• W2018183727 hasConceptScore W2018183727C2778261982 @default.
• W2018183727 hasConceptScore W2018183727C2778382381 @default.
• W2018183727 hasConceptScore W2018183727C2778589496 @default.
• W2018183727 hasConceptScore W2018183727C2779161974 @default.
• W2018183727 hasConceptScore W2018183727C2780077467 @default.
• W2018183727 hasConceptScore W2018183727C2780434524 @default.
• W2018183727 hasConceptScore W2018183727C2992139802 @default.
• W2018183727 hasConceptScore W2018183727C42219234 @default.
• W2018183727 hasConceptScore W2018183727C43376680 @default.
• W2018183727 hasConceptScore W2018183727C71924100 @default.

• next